RAPT Therapeutics (RAPT) EBT (2020 - 2023)
Historic EBT for Therapeutics (RAPT) over the last 4 years, with Q4 2023 value amounting to -$33.2 million.
- Therapeutics' EBT fell 3596.25% to -$33.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$127.1 million, marking a year-over-year decrease of 4809.95%. This contributed to the annual value of -$127.1 million for FY2023, which is 4809.95% down from last year.
- Latest data reveals that Therapeutics reported EBT of -$33.2 million as of Q4 2023, which was down 3596.25% from -$33.9 million recorded in Q3 2023.
- Therapeutics' EBT's 5-year high stood at -$12.1 million during Q2 2020, with a 5-year trough of -$33.9 million in Q3 2023.
- Moreover, its 4-year median value for EBT was -$18.8 million (2021), whereas its average is -$20.9 million.
- In the last 5 years, Therapeutics' EBT crashed by 1622.97% in 2022 and then plummeted by 5646.74% in 2023.
- Over the past 4 years, Therapeutics' EBT (Quarter) stood at -$12.5 million in 2020, then plummeted by 43.02% to -$17.9 million in 2021, then plummeted by 36.27% to -$24.4 million in 2022, then tumbled by 35.96% to -$33.2 million in 2023.
- Its EBT stands at -$33.2 million for Q4 2023, versus -$33.9 million for Q3 2023 and -$28.4 million for Q2 2023.